Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro

Journal of International Medical Research

Volumn 41, Issue 5, 2013, Pages 1505-1519

  Lou, Zhiyuan ^a   Ren, Tingting ^a   Peng, Xianbo ^a   Sun, Yifeng ^a   Jiao, Guangjun ^a   Lu, Qunshan ^a   Zhang, Shuai ^a   Lu, Xinchang ^a   Guo, Wei ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; autophagy; bortezomib; cell cycle arrest; mitogen activated protein kinase (MAPK); osteosarcoma; proteasome inhibition; transmission electron microscopy (TEM)

Indexed keywords

BORTEZOMIB; CELL ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOSARCOMA CELL; SIGNAL TRANSDUCTION;

APOPTOSIS; AUTOPHAGY; BORTEZOMIB; CELL-CYCLE ARREST; MITOGEN-ACTIVATED PROTEIN KINASE (MAPK); OSTEOSARCOMA; PROTEASOME INHIBITION; TRANSMISSION ELECTRON MICROSCOPY (TEM);

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZINES; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84887275715     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513490618     Document Type: Article

References (33)

1. Ottaviani G,Jaffe N.The epidemiology of osteosarcoma.Cancer Treat Res. 2010;152:3-13.
2. PosthumaDeBoer J,Witlox M,Kaspers GJ, et al.Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.Clin Exp Metastasis. 2011;28:493-503.
3. Gazitt Y,Kolaparthi V,Moncada K, et al.Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.Int J Oncol. 2009;34:551-551.
4. Yang W,Liu X,Choy E, et al.Targeting hedgehog-GLI-2 pathway in osteosarcoma.J Orthop Res. 2013;31:502-509.
5. Smalley KS,Haass NK,Brafford PA, et al.Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.Mol Cancer Ther. 2006;5:1136-1144.
6. Dalla Via L,Nardon C,Fregona D.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Future Med Chem. 2012;4:525-543.
7. Chen D,Frezza M,Schmitt S, et al.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Curr Cancer Drug Targets. 2011;11:239-253.
8. Kane RC,Farrell AT,Sridhara R, et al.United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.Clin Cancer Res. 2006;12:2955-2960.
9. Adams J.The proteasome: a suitable antineoplastic target.Nat Rev Cancer. 2004;4:349-360.
10. Williams SA,McConkey DJ.The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.Cancer Res. 2003;63:7338-7344.
11. Cui Q,Tashiro S,Onodera S, et al.Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells.Biol Pharm Bull. 2007;30:859-864.
12. Lockshin RA,Zakeri Z.Apoptosis, autophagy, and more.Int J Biochem Cell Biol. 2004;36:2405-2419.
13. Wagner EF,Nebreda ÁR.Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer. 2009;9:537-549.
14. Yu C,Rahmani M,Dent P, et al.The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.Exp Cell Res. 2004;295:555-566.
15. Yu C,Rahmani M,Almenara J, et al.Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells.Cancer Res. 2003;63:2118-2126.
16. Bonvini P,Zorzi E,Basso G, et al.Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.Leukemia. 2007;21:838-842.
17. Lu G,Punj V,Chaudhary PM.Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.Cancer Biol Ther. 2008;7:603-608.
18. Moriceau G,Roelofs AJ,Brion R, et al.Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.Cancer. 2012;118:750-760.
19. Liu XS,Jiang J.Induction of apoptosis and regulation of the MAPK pathway by ursolic acid in human leukemia K562 cells.Planta Med. 2007;73:1192-1194.
20. Hong YS,Hong SW,Kim SM, et al.Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.Int J Oncol. 2012;41:76-82.
21. Oliver FJ,de la Rubia G,Rolli V, et al.Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant.J Biol Chem. 1998;273:33533-33539.
22. Poulaki V,Mitsiades CS,Kotoula V, et al.The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.Invest Ophthalmol Vis Sci. 2007;48:4706-4719.
23. Shapovalov Y,Benavidez D,Zuch D, et al.Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma.Int J Cancer. 2010;127:67-76.
24. Liu L,Yang M,Kang R, et al.HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.Leukemia. 2010;25:23-31.
25. Kabeya Y,Mizushima N,Ueno T, et al.LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.EMBO J. 2000;19:5720-5728.
26. Pankiv S,Clausen TH,Lamark T, et al.p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy.J Biol Chem. 2007;282:24131-24145.
27. Pandit B,Gartel AL.FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy.Cell Cycle. 2011;10:3269-3273.
28. Lemasters JJ,Nieminen AL,Qian T, et al.The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy.Biochim Biophys Acta. 1998;1366:177-196.
29. Caro LH,Plomp PJ,Wolvetang EJ, et al.3-Methyladenine, an inhibitor of autophagy, has multiple effects on metabolism.Eur J Biochem. 1988;175:325-329.
30. Zhang W,Liu HT.MAPK signal pathways in the regulation of cell proliferation in mammalian cells.Cell Res. 2002;12:9-18.
31. Lee JC,Kassis S,Kumar S, et al.p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials.Pharmacol Ther. 1999;82:389-397.
32. Leleu X,Eeckhoute J,Jia X, et al.Targeting NF-kappaB in Waldenstrom macroglobulinemia.Blood. 2008;111:5068-5077.
33. Xia Z,Dickens M,Raingeaud J, et al.Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.Science. 1995;270:1326-1331.